124 related articles for article (PubMed ID: 11143821)
1. Excellent response to interferon therapy in a patient with hypereosinophilic syndrome and elevated serum immunoglobulin E levels.
Acaba L; Mangual A; Vélez García E
Bol Asoc Med P R; 2000; 92(4-8):59-62. PubMed ID: 11143821
[TBL] [Abstract][Full Text] [Related]
2. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.
Carruthers MN; Park S; Slack GW; Dalal BI; Skinnider BF; Schaeffer DF; Dutz JP; Law JK; Donnellan F; Marquez V; Seidman M; Wong PC; Mattman A; Chen LY
Eur J Haematol; 2017 Apr; 98(4):378-387. PubMed ID: 28005278
[TBL] [Abstract][Full Text] [Related]
3. [Alpha interferon treatment in idiopathic hypereosinophilic syndrome resistant to conventional therapy].
Esteve J; Cervantes F; Bosch F; Cobo F; Montserrat E; Rozman C
Med Clin (Barc); 1996 Mar; 106(8):304-6. PubMed ID: 8667689
[TBL] [Abstract][Full Text] [Related]
4. Mucosal ulcerations revealing primitive hypereosinophilic syndrome.
Barouky R; Bencharif L; Badet F; Salles G; Vital Durand D; Rousset H
Eur J Dermatol; 2003; 13(2):207-8. PubMed ID: 12695143
[TBL] [Abstract][Full Text] [Related]
5. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
Bockenstedt PL; Santinga JT; Bolling SF
Am J Hematol; 1994 Mar; 45(3):248-51. PubMed ID: 8296798
[TBL] [Abstract][Full Text] [Related]
6. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
7. [The hypereosinophilic syndrome].
Jegou J; Barete S; Frances C
Ann Dermatol Venereol; 2003; 130(6-7):664-6. PubMed ID: 13679710
[No Abstract] [Full Text] [Related]
8. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon.
Butterfield JH
Immunol Allergy Clin North Am; 2007 Aug; 27(3):493-518. PubMed ID: 17868861
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
10. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
Butterfield JH
Acta Haematol; 2005; 114(1):26-40. PubMed ID: 15995323
[TBL] [Abstract][Full Text] [Related]
11. Hypereosinophilic syndrome: an update.
Wilkins HJ; Crane MM; Copeland K; Williams WV
Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
[TBL] [Abstract][Full Text] [Related]
12. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.
Lee CH; Mamelak AJ; Vonderheid EC
Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344
[TBL] [Abstract][Full Text] [Related]
13. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.
Butterfield JH; Gleich GJ
Ann Intern Med; 1994 Nov; 121(9):648-53. PubMed ID: 7944072
[TBL] [Abstract][Full Text] [Related]
15. Superficial venous thrombophlebitis as the initial manifestation of hypereosinophilic syndrome: study of the first 3 cases.
Terrier B; Piette AM; Kerob D; Cordoliani F; Tancrède E; Hamidou L; Lebbé C; Blétry O; Kahn JE
Arch Dermatol; 2006 Dec; 142(12):1606-10. PubMed ID: 17178987
[TBL] [Abstract][Full Text] [Related]
16. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review.
Yoon TY; Ahn GB; Chang SH
J Dermatol; 2000 Feb; 27(2):110-5. PubMed ID: 10721659
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic hypereosinophilic syndrome: a report of four cases in Arabs, and a review of the literature.
George BO; Abdelaal MA; Gangi MT; Kinsara AJ
Afr J Med Med Sci; 2001 Sep; 30(3):241-9. PubMed ID: 14510138
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.
Choi C; Moller D; Tan J; Dou C; Peterson EA; Medvedev N; Dutz JP; Carruthers MN; Chen LYC
Br J Haematol; 2020 Mar; 188(5):e68-e72. PubMed ID: 31721154
[No Abstract] [Full Text] [Related]
19. [The eosinophil: doctor Jekyll or mister Hyde?].
Bletry O
Med Trop (Mars); 1998; 58(4 Suppl):423-5. PubMed ID: 10410359
[No Abstract] [Full Text] [Related]
20. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
